Filtered By:
Condition: Atrial Fibrillation
Infectious Disease: COVID-19

This page shows you your search results in order of relevance. This is page number 8.

Order by Relevance | Date

Total 196 results found since Jan 2013.

Association between oral anticoagulants and COVID-19-related outcomes: a population-based cohort study
CONCLUSION: Among those at low baseline stroke risk, people receiving OACs had a lower risk of testing positive for SARS-CoV-2 and severe COVID-19 outcomes than non-users; this might be explained by a causal effect of OACs in preventing severe COVID-19 outcomes or unmeasured confounding, including more cautious behaviours leading to reduced infection risk.PMID:35440465 | DOI:10.3399/BJGP.2021.0689
Source: The British Journal of General Practice - April 20, 2022 Category: Primary Care Authors: Angel Ys Wong Laurie Tomlinson Jeremy P Brown William Elson Alex J Walker Anna Schultze Caroline E Morton David Evans Peter Inglesby Brian MacKenna Krishnan Bhaskaran Christopher T Rentsch Emma Powell Elizabeth Williamson Richard Croker Seb Bacon William Source Type: research

Evaluation of antithrombotic use and COVID-19 outcomes in a nationwide atrial fibrillation cohort
Conclusions Pre-existing AT use may be associated with lower odds of COVID-19 death and, while not evidence of causality, provides further incentive to improve AT coverage for eligible individuals with AF.
Source: Heart - May 25, 2022 Category: Cardiology Authors: Handy, A., Banerjee, A., Wood, A. M., Dale, C., Sudlow, C. L. M., Tomlinson, C., Bean, D., Thygesen, J. H., Mizani, M. A., Katsoulis, M., Takhar, R., Hollings, S., Denaxas, S., Walker, V., Dobson, R., Sofat, R., on behalf of the CVD-COVID-UK Consortium Tags: Open access, COVID-19 Cardiac risk factors and prevention Source Type: research

Impact of apixaban treatment discontinuation on the risk of hospitalization among patients with nonvalvular atrial fibrillation and COVID-19
CONCLUSION: NVAF patients with COVID-19 who discontinued apixaban had a higher risk of hospitalization and thrombotic events vs. those who continued apixaban, with no significant difference in bleeding-related hospitalization.PMID:36000258 | DOI:10.1080/03007995.2022.2112871
Source: Current Medical Research and Opinion - August 24, 2022 Category: Research Authors: Steven Deitelzweig Julia Zhu Jenny Jiang Xuemei Luo Allison Keshishian Mauricio Ferri Lisa Rosenblatt Patricia Schuler Cynthia Gutierrez Amol D Dhamane Source Type: research

Proportion of Patients on Warfarin Therapy Who Are Eligible for Conversion to a Direct Oral Anticoagulant in the Setting of COVID-19
CONCLUSION AND RELEVANCE: Approximately 52% of patients on warfarin were eligible for DOACs. This presents an opportunity to reduce patient exposure to health care settings and health care utilization in the setting of COVID-19. Increased costs of DOACs need to be assessed.PMID:36373362 | DOI:10.1177/10600280221136874
Source: The Annals of Pharmacotherapy - November 14, 2022 Category: Drugs & Pharmacology Authors: Rachel Hess Elizabeth Renner Erin Mouland Denise Sutter-Long Nghi Ha Source Type: research

Cardiovascular-related conditions and risk factors in primary care for deprived communities before and during the COVID-19 pandemic: an observational study in Northern England
Conclusion Recorded CVD-related risk factors and conditions remained comparable before and during COVID-19. These are higher in the Deep End than in England and similar or lower than the non-Deep End, with a higher optimal statin prescribing rate. However, it was not possible to control for age and sex. More work is needed to estimate the consequences of the pandemic on disadvantaged communities and to compare whether the findings are replicated in other areas of deprivation.
Source: BMJ Open - November 22, 2022 Category: General Medicine Authors: Fu, Y., Price, C., Haining, S., Gaffney, B., Julien, D., Whitty, P., Newton, J. L. Tags: Open access, Public health, COVID-19 Source Type: research

Heartbeat: hospitalisation for COVID-19 is associated with an increased risk of subsequent adverse cardiovascular events
In order to assess whether previous COVID-19 infection might be associated with a higher risk of subsequent adverse cardiovascular disease (CVD) events, Raisi-Estabragh and colleagues1 analysed incident CVD events in 17 871 UK Biobank cases with prospective follow-up from March 2020 to March 2021. Hospitalisation for COVID-19 was associated with an increased risk of several adverse CVD events, including myocardial infarction, stroke, heart failure, atrial fibrillation, venous thromboembolism and mortality (figure 1). Risk was highest in the first 30 days after infection, but remained higher than matched controls over an av...
Source: Heart - December 22, 2022 Category: Cardiology Authors: Otto, C. M. Tags: COVID-19 Highlights from this issue Source Type: research

Comparison of thromboembolic risk scores for evaluating in-hospital events of COVID-19 patients
Conclusion: We showed that m-R2CHA2DS2-VASc and m-ATRIA-HSV scores were better than the rest in predicting mortality among COVID-19 patients.PMID:37038968 | DOI:10.2217/bmm-2022-0546
Source: Future Medicine: Biomarkers in Medicine - April 11, 2023 Category: Internal Medicine Authors: Ömer Genç Abdullah Yildirim M ürşide Genç Fahri Er G ökhan Alici Alaa Quisi Hazar Harbalio ğlu Samir Allahverdiyev İbrahim H Kurt Source Type: research